Investor and Analyst Webcast with Expert Oncologists
Date and Time: Friday, June 4, 2021, at 4:00 p.m. ET (
Dial-in: +1 877-407-2988 for
Investors and analysts can also view slides and listen to the live audio webcast of the presentation on the Investors section of Alkermes' website at www.alkermes.com. A replay of the webcast will be archived on the company's website for 30 days following the presentation.
Nemvaleukin Poster Presentations at ASCO
Title: ARTISTRY-1: Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Presentation Date/Time: The on-demand poster discussion session will take place on
Title: Selection of the Recommended Phase 2 Dose (RP2D) for Subcutaneous Nemvaleukin Alfa: ARTISTRY-2
Presentation Date: The poster presentation will be available on-demand to attendees beginning
About Nemvaleukin alfa ("nemvaleukin")
Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.
About the ARTISTRY Clinical Development Program
ARTISTRY is an Alkermes-sponsored clinical development program evaluating nemvaleukin alfa as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous and subcutaneous dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. Ongoing trials include: ARTISTRY-1, ARTISTRY-2, ARTISTRY-3 and ARTISTRY-6.
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of
For Media: Sourojit Bhowmick, Ph.D. +1 781 609 6397
View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-to-host-webcast-with-expert-oncologist-panel-to-discuss-data-on-nemvaleukin-alfa-presented-at-2021-american-society-of-clinical-oncology-asco-annual-meeting-301301872.html